Vascular Endothelial Growth Factor A (VEGFA) Antibody

Este producto es parte de VEGFA - Vascular Endothelial Growth Factor A
Product Graph
221€ (50 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Vascular Endothelial Growth Factor A (VEGFA) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx326466
tested applications
ELISA, IHC

Description

VEGFA Antibody is a Rabbit Polyclonal against VEGFA.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Vascular Endothelial Growth Factor A (VEGFA)
Host
Rabbit
Reactivity
Human, Mouse, Rat
Recommended Dilution
ELISA: 1/10000, IHC: 1/100 - 1/300. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Purified by affinity chromatography.
Size 1
50 µg
Size 2
100 µg
Form
Liquid
Tested Applications
ELISA, IHC
Buffer
PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P15692
Gene ID
7422
Alias
L-VEGF,MVCD1,VEGF,VPF,Vascular permeability factor
Background
Antibody anti-VEGFA
Status
RUO

Descripción

VEGFA is a key member of the vascular endothelial growth factor (VEGF) family and plays a crucial role in angiogenesis, vascular permeability, and endothelial cell proliferation VEGFA binds primarily to its receptors VEGFR-1 and VEGFR-2, triggering signaling pathways like PI3K/AKT and ERK/MAPK to promote blood vessel formation during embryonic development, wound healing, and tissue repair Dysregulated VEGFA expression is associated with pathological angiogenesis observed in cancer, diabetic retinopathy, and age-related macular degeneration (AMD) VEGFA also increases vascular permeability by altering endothelial junctions, contributing to fluid leakage in conditions such as inflammation and tumors Targeted therapies, such as bevacizumab and other anti-VEGF agents, inhibit VEGFA activity to suppress angiogenesis and tumor growth in various cancers and ocular diseases

Related Products

EG0049

Goat VEGF-A (Vascular Endothelial cell Growth Factor A) ELISA Kit

Ver Producto
EGP0053

Guinea pig VEGF-A (Vascular Endothelial cell Growth Factor A) ELISA Kit

Ver Producto
FNab09391

VEGFA antibody

VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1(MVCD1). VEGFA has 13 isoforms with MW 16kd to 45kd. Some isoforms has homodimer form, such as VEGFA189(38kd), VEFGA110(34kd). VEGFA is a 34kd to 42kd, dimeric, disulfide-bound glycoprotein. VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids(PMID:15602010).

Ver Producto